Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

被引：0
|
作者：
Rita Nahta
Dihua Yu
Mien-Chie Hung
Gabriel N Hortobagyi
Francisco J Esteva
机构：
[1] Instructor at the Department of Breast Medical Oncology,Departments of Breast Medical Oncology and Molecular & Cellular Oncology
[2] Professor at the Departments of Surgical Oncology and Molecular and Cellular Oncology,undefined
[3] Professor in the Department of Molecular and Cellular Oncology,undefined
[4] Chairman and Professor in the Department of Breast Medical Oncology,undefined
[5] Director of the Breast Cancer Translational Research Laboratory and Associate Professor,undefined
[6] University of Texas MD Anderson Cancer Center,undefined
来源：
Nature Clinical Practice Oncology | 2006年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Despite the impressive results seen in phase II trials of trastuzumab, many tumors that overexpress HER2 show resistance to the drug. Understanding the molecular mechanisms underlying primary or treatment-induced trastuzumab resistance is critical to improving the survival of patients with metastatic breast cancer with aggressive HER2 overexpressing tumors. This review discusses the novel therapeutic strategies that target the aberrant molecular pathways, and explains how these strategies could greatly improve the duration of response to trastuzumab.
引用
收藏
页码：269 / 280
页数：11
相关论文
共 50 条
  • [1] Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
    Nahta, Rita
    Yu, Dihua
    Hung, Mien-Chie
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (05): : 269 - 280
  • [2] Molecular mechanisms of resistance to HER2-targeted therapy
    FJ Esteva
    Breast Cancer Research, 11
  • [3] Molecular mechanisms of resistance to HER2-targeted therapy
    Esteva, F. J.
    BREAST CANCER RESEARCH, 2009, 11 : S10 - S10
  • [4] Mechanisms of Resistance to HER2-Targeted Therapies in HER2-positive Breast Cancer
    Veeraraghavan, Jamunarani
    Liao, Fu-Tien
    Qin, Lanfang
    Gordon, Tia
    Raghavan, Alekya
    Sabotta, Caroline
    Kaplan, Rachel
    Gutierrez, Carolina
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    Schiff, Rachel
    CANCER RESEARCH, 2024, 84 (03)
  • [5] Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer
    Zhang, Rui
    Su, Chang
    Jia, Yongliang
    Xing, Menglu
    Jin, Shuiling
    Zong, Hong
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 179
  • [6] Role of Fcγ receptors in HER2-targeted breast cancer therapy
    Musolino, Antonino
    Gradishar, William J.
    Rugo, Hope S.
    Nordstrom, Jeffrey L.
    Rock, Edwin P.
    Arnaldez, Fernanda
    Pegram, Mark D.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [7] Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review
    Blange, Dionne
    Stroes, Charlotte I.
    Derks, Sarah
    Bijlsma, Maarten F.
    van Laarhoven, Hanneke W. M.
    CANCER TREATMENT REVIEWS, 2022, 108
  • [8] Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
    Sharial, M. S. N. Mohd
    Crown, J.
    Hennessy, B. T.
    ANNALS OF ONCOLOGY, 2012, 23 (12) : 3007 - 3016
  • [9] HER2-targeted therapy influences CTC status in metastatic breast cancer
    Thomas M. Deutsch
    Sabine Riethdorf
    Carlo Fremd
    Manuel Feisst
    Juliane Nees
    Chiara Fischer
    Andreas D. Hartkopf
    Klaus Pantel
    Andreas Trumpp
    Florian Schütz
    Andreas Schneeweiss
    Markus Wallwiener
    Breast Cancer Research and Treatment, 2020, 182 : 127 - 136
  • [10] HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
    Dent, Susan
    Oyan, Basak
    Honig, Amd
    Mano, Max
    Howell, Sacha
    CANCER TREATMENT REVIEWS, 2013, 39 (06) : 622 - 631
12345